Roberta Fachini Jardim Criado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roberta Fachini Jardim Criado has a total of 622 co-authors. Here are the top co-authors by number of shared publications:
- Paulo Ricardo Criado
Centro Universitário Faculdade de Medicina do ABC, Santo André, SP, Brazil; Faculdade de Ciências Médicas de Santos (Fundação Lusíada), Santos, SP, Brazil
26 shared publications - Ana Maria Giménez Arnau
Department of Dermatology Hospital del Mar Research Institute Barcelona Spain
18 shared publications - Alicja Kasperska-Zajac
European Center for Diagnosis and Treatment of Urticaria Medical University of Silesia Katowice Poland
14 shared publications - Marcus Maurer
Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
13 shared publications - Luis Felipe Ensina
Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics Federal University of São Paulo São Paulo Brazil
11 shared publications - Hélio Amante Miot
Department of Infectology, Dermatology, Imaging Diagnosis and Radiotherapy, Faculty of Medicine, Universidade Estadual Paulista, Botucatu, SP, Brazil
10 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (3) , 631-645
Factors Associated with Symptomatic Dermographism: Findings from the UCARE PREVALENCE-D Study
Background and Objective Symptomatic dermographism (SD), the most common chronic inducible urticaria subtype, manifests as strip-shaped, pruritic wheals after skin friction. Conclusive data on its associated factors are limited, and direct comparisons between individuals with and without SD remain scarce. We aimed to identify factors associated with SD internationally. Methods The PREVALENCE-D (Prevalence Estimation of Dermographism) study was an international cross-sectional survey conducted from 2021 to 2024 across 19 countries. An expert-designed questionnaire diagnosed SD and assessed potential associated factors. SD participants were defined as those who self-reported chronic recurrent urticarial dermographism with itch. Factors associated with SD were identified by comparing participants with and without SD. Results Of 68,513 participants, 3101 had SD (female 73.3%). Their mean age was 40.2 ± 16.2 years. Key factors associated with SD included atopic dermatitis (adjusted odds ratio [aOR] 4.20, 95% confidence interval [CI] 3.62‒4.88) and allergic rhinitis (aOR 2.11, 95% CI 1.88‒2.37). Participants with at least one atopic condition (allergic rhinitis, atopic dermatitis, or asthma) were significantly more likely to have SD (aOR 2.70, 95% CI 2.47‒2.95). Those with all three atopic conditions had a further increased likelihood of SD (aOR 7.75, 95% CI 5.31‒11.29). Other associations included working and older age groups, female sex, dyslipidemia, and thyroid disease. Conclusions Atopic dermatitis and allergic rhinitis emerged as the strongest correlates of SD, especially those with all three atopic conditions. Thus, allergic comorbidities should be assessed in SD patients. Further research is needed to clarify the pathophysiological relationship between these conditions and SD. [Graphical abstract available online] Graphical Abstract
- 17 March 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (3) , 631-645
Open AccessFactors Associated with Symptomatic Dermographism: Findings from the UCARE PREVALENCE-D Study
Background and Objective Symptomatic dermographism (SD), the most common chronic inducible urticaria subtype, manifests as strip-shaped, pruritic wheals after skin friction. Conclusive data on its associated factors are limited, and direct comparisons between individuals with and without SD remain scarce. We aimed to identify factors associated with SD internationally. Methods The PREVALENCE-D (Prevalence Estimation of Dermographism) study was an international cross-sectional survey conducted from 2021 to 2024 across 19 countries. An expert-designed questionnaire diagnosed SD and assessed potential associated factors. SD participants were defined as those who self-reported chronic recurrent urticarial dermographism with itch. Factors associated with SD were identified by comparing participants with and without SD. Results Of 68,513 participants, 3101 had SD (female 73.3%). Their mean age was 40.2 ± 16.2 years. Key factors associated with SD included atopic dermatitis (adjusted odds ratio [aOR] 4.20, 95% confidence interval [CI] 3.62‒4.88) and allergic rhinitis (aOR 2.11, 95% CI 1.88‒2.37). Participants with at least one atopic condition (allergic rhinitis, atopic dermatitis, or asthma) were significantly more likely to have SD (aOR 2.70, 95% CI 2.47‒2.95). Those with all three atopic conditions had a further increased likelihood of SD (aOR 7.75, 95% CI 5.31‒11.29). Other associations included working and older age groups, female sex, dyslipidemia, and thyroid disease. Conclusions Atopic dermatitis and allergic rhinitis emerged as the strongest correlates of SD, especially those with all three atopic conditions. Thus, allergic comorbidities should be assessed in SD patients. Further research is needed to clarify the pathophysiological relationship between these conditions and SD. [Graphical abstract available online] Graphical Abstract
- Top Cited PapersOpen Access
The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria
This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA 2 LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), with the participation of 210 delegates from 107 national and international societies, from 59 countries. The consensus conference was held on December 6th, 2024. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell‐driven disease, defined by a rapid appearance of wheals, angioedema, or both. The lifetime prevalence of acute urticaria is estimated to be approximately 20%. Chronic urticaria, categorized as either chronic spontaneous urticaria or chronic inducible urticaria, is disabling, impairs quality of life, and affects performance at work and school, however, novel therapies are available. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert‐guided and evidence‐based diagnostic and therapeutic approaches for the different subtypes of urticaria.
Top Cited PapersOpen AccessThe International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria
This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA 2 LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), with the participation of 210 delegates from 107 national and international societies, from 59 countries. The consensus conference was held on December 6th, 2024. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell‐driven disease, defined by a rapid appearance of wheals, angioedema, or both. The lifetime prevalence of acute urticaria is estimated to be approximately 20%. Chronic urticaria, categorized as either chronic spontaneous urticaria or chronic inducible urticaria, is disabling, impairs quality of life, and affects performance at work and school, however, novel therapies are available. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert‐guided and evidence‐based diagnostic and therapeutic approaches for the different subtypes of urticaria.
- Open Access
The Prevalence of Symptomatic Dermographism: Results of the International UCARE PREVALENCE ‐D Study
Background: The prevalence of symptomatic dermographism ( SD ) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes—physiological red dermographism and simple urticarial dermographism—among adults worldwide. Methods: The PREVALENCE ‐D (Prevalence Estimation of Dermographism) study was the largest international, cross‐sectional, internet‐based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert‐designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD . Participants were recruited into three age groups (18–24, 25–60, and > 60 years), with ≥ 1000 individuals per group per country. We calculated sex‐ and age‐adjusted prevalence estimates internationally and by country, with 95% confidence intervals. Results: Among 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [ CI ] 2.68%–3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%–6.56%). The 25–60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%–10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%–34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%–1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%–5.79%). Conclusion: These findings provide comprehensive international estimates of dermographism, particularly SD , and emphasize the need for appropriate healthcare resource allocation and disease recognition.
Open AccessThe Prevalence of Symptomatic Dermographism: Results of the International UCARE PREVALENCE ‐D Study
Background: The prevalence of symptomatic dermographism ( SD ) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes—physiological red dermographism and simple urticarial dermographism—among adults worldwide. Methods: The PREVALENCE ‐D (Prevalence Estimation of Dermographism) study was the largest international, cross‐sectional, internet‐based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert‐designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD . Participants were recruited into three age groups (18–24, 25–60, and > 60 years), with ≥ 1000 individuals per group per country. We calculated sex‐ and age‐adjusted prevalence estimates internationally and by country, with 95% confidence intervals. Results: Among 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [ CI ] 2.68%–3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%–6.56%). The 25–60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%–10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%–34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%–1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%–5.79%). Conclusion: These findings provide comprehensive international estimates of dermographism, particularly SD , and emphasize the need for appropriate healthcare resource allocation and disease recognition.
- Open Access
- 2 September 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (5)
Urticária crônica espontânea: atualização na patogênese e implicações terapêuticas
- 2 September 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (5)
Open AccessUrticária crônica espontânea: atualização na patogênese e implicações terapêuticas
- Open Access
- 21 August 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (5) , 501198
Chronic spontaneous urticaria: update on pathogenesis and therapeutic implications
- 21 August 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (5) , 501198
Open AccessChronic spontaneous urticaria: update on pathogenesis and therapeutic implications
- 23 July 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (1)
Mucosal angioedema involving the oropharynx signals severe cold urticaria: COLD ‐ CE study insights
- 23 July 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (1)
Mucosal angioedema involving the oropharynx signals severe cold urticaria: COLD ‐ CE study insights
- Open Access
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 487-519
Prurido crônico: revisão narrativa
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 487-519
Open AccessPrurido crônico: revisão narrativa
- Open Access
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 470-486
O impacto da dermatite atópica na prática clínica: resultados do MEASURE‐AD do Brasil, México e Argentina
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 470-486
Open AccessO impacto da dermatite atópica na prática clínica: resultados do MEASURE‐AD do Brasil, México e Argentina
- Open Access
- 3 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 487-519
Chronic pruritus: a narrative review
- 3 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 487-519
Open AccessChronic pruritus: a narrative review